Real-world progression-free survival with erlotinib versus osimertinib in EGFR L858R + T790M compound mutation non-small cell lung Cancer: An exploratory analysis of the MSK-CHORD dataset

Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles